Introduction
Remarkable progress in the understanding of cystic fibrosis (CF) pathogenesis has led to a number of therapeutic opportunities in the disease [1] . Several therapies including mucolytics, inhaled antimicrobials, systemic anti-inflammatories, and nutritional support are the mainstays of CF treatment, and these supportive therapies are largely responsible for the marked improvement in life expectancy over time, resulting in a median survival of 37 years [2] . Based on the discovery of the CF gene by Collins, Riordan, and Tsui [3] [4] [5] , coupled with our emerging understanding of the function of its gene product, the cystic fibrosis transmembrane conductance regulator (CFTR), new treatments that target the basic ion transport defect in the disease are now in various stages of development, and promise to complement supportive therapies already available to patients. Recent progress in the treatment strategies that target CFTR through protein repair will be described here. Other promising treatment strategies that intend to circumvent CFTR by restoring depleted airway surface liquid and augmenting mucus clearance through osmotic forces in the airway, activate alternative chloride transporters or inhibit hyperactive sodium absorption through the epithelial sodium channel, and replacement of the CFTR gene itself through gene therapy are reviewed elsewhere [6, 7] .
Cystic fibrosis transmembrane conductance regulator mutations and molecular approaches to protein repair CFTR is an epithelial ion channel expressed in exocrine glands that conducts chloride and bicarbonate across the plasma membrane and regulates transepithelial transport of sodium. Absence of functional CFTR in CF engenders gross dysfunction of multiple organs, causing excess morbidity and early mortality owing to mucus obstruction and leading to profound pulmonary failure [7] .
to therapeutic strategies based on the particular mutation type (Fig. 1 ). Class I mutations include premature termination codons (PTCs, e.g. nonsense mutations) within the coding region of CFTR, which cause premature truncation of normal protein translation. These mutations are found in 10% of CF patients, but are particularly common in Ashkenazi Jews (75% of mutant CFTR alleles) [8] . Class II CFTR mutations include F508del CFTR, the most common mutation in humans (accounting for 75% of alleles and found in approximately 90% of CF patients). The deletion of phenylalanine at the 508 position causes CFTR to exhibit abnormal folding characterized by deficient stabilization by domain-domain interactions between the nucleotidebinding domain 1 (NBD1) and the transmembrane domains [9, 10 ] . The misfolded protein is recognized by cellular chaperones within the endoplasmic reticulum (ER), directed to the proteasome, and rapidly degraded prior to reaching its active site at the cell surface. Because the cellular machinery responsible for the recognition and degradation of the misfolded protein is not 100% efficient, particular individuals exhibit low levels of surface expression of F508del CFTR, which may account for partial CFTR activity (and a more mild CF phenotype) observed in individuals homozygous for F508del CFTR, and could represent a population more amenable to protein repair [11] . Even when at the cell surface, F508del CFTR exhibits reduced gating, suggesting that misfolded CFTR also exhibits reduced CFTR ion channel activity.
Class III and IV CFTR mutations are characterized by full-length CFTR that reaches the cell surface but exhibit reduced ion transport activity owing to abnormal channel gating (Class III, e.g. G551D) or reduced conductivity of the ion channel pore (Class IV, e.g. R117H). Similarly, splicing mutants (Class V) and mutations within the C-terminus (Class VI) are also full length, but exhibit reduced activity owing to reduced numbers of active channels within the plasma membrane [12, 13] .
Although the molecular basis of CFTR mutants is complex and as yet incomplete, the classification of CFTR mutants can be simplified into the therapeutically relevant groups based on the activity of agents in development. Both traditional and high-throughput drug discovery programs have resulted in discovery of novel compounds that address specific mutant CFTR alleles. These 'CFTR modulators' are pharmacological agents intended to repair the CFTR protein and are described in Classes of defects in the cystic fibrosis transmembrane conductance regulator (CFTR) gene include PTCs causing truncated protein translation (class I); misfolded CFTR, including deletion of phenylalanine at position 508 (class II); full-length CFTR that reaches the cell surface, but exhibits abnormal channel gating (class III) or reduced pore conductivity (class IV); CFTR with splicing errors that reduce surface expression (class V); and C-terminus mutations (class VI) that reduce membrane residence time. PTC suppressors (e.g. aminoglycosides and ataluren) bind to ribosomal subunits (green star) to allow suppression of PTCs and expression of full-length protein. Class II mutations like F508del can respond to small-molecule corrector compounds to restore folding defects and/or enhance expression of the channel at the cell membrane. Without correction, almost all F508del CFTR is shunted to the proteosome, leaving detectable surface protein in only select individuals. CFTR potentiators are currently in human clinical trials (VX-770, green chevron) for patients with G551D and F508del CFTR. Future directions include exploring the use of CFTR potentiators for other CFTR mutations known to reside at the cell surface. Combination therapy with potentiators has also been proposed for classes I and II CFTR mutations. PTC, premature termination codon. each section that follows. Although the molecular defect of many CFTR mutants have not been fully characterized, ongoing efforts within the international 'CFTR2' project are intended to systematically catalog the phenotype associated with reported CFTR mutations, and will be complemented with functional and biochemical measures of CFTR activity and expression in vitro. These data should provide a path for systematic categorization of many CFTR mutations commonly present in the CF population, and provide guidance as to the most applicable therapy for each specific mutation.
Potentiators of cell-surface cystic fibrosis transmembrane conductance regulator
CFTR mutation classes that result in dysfunctional CFTR that resides at the plasma membrane include Class III, IV, V, and VI mutations and represent potential targets for CFTR activators. G551D CFTR represents an archetype CFTR allele for this category of agents, as it exhibits normal surface expression and half-life, but confers a severe defect in channel gating owing to an amino acid substitution in the adenosine triphosphate (ATP) binding pocket within the nucleotide binding domains [14] . Flavonoids are well known activators of mutant CFTR and were among the first to be studied for beneficial effects in human individuals (including topical administration) [15] . Although agents such as genistein were affected by lack of efficacy in the nasal airway, more recent efforts have demonstrated activity of the flavonoid quercetin in the nose [16] . However, flavonoid agents are challenged by poor solubility and systemic absorption, and are poor development candidates for inhaled therapeutics.
More recent discovery strategies have focused on identification of compounds that 'potentiate' CFTR activity, restoring endogenous regulation (e.g. cyclic adenosine monosphosphate (cAMP)-dependent regulation) and ion transport without excessive, constitutive activation that may potentially be detrimental (such as excessive CFTR activation seen with certain diarrheal illnesses) [17] . Identification of agents of this type is amenable to high-throughput screening-based strategies to discover agents that activate mutant CFTR by measuring the effects on anion conductance in cell-based screening assays. A number of specific strategies have been used for screens of this sort, including chloride sensitive dyes [18, 19] , fluorescence resonance energy transfer-based analysis of membrane potential [17] , and cell conductance of airway monolayers [20] . Identification and characterization of small molecule potentiators of mutant CFTR have led to the development of agents with pronounced activity in vitro and in the clinic. Secondary testing of a lead compound developed by Vertex Phar-maceuticals (Cambridge, Massachusetts, USA), VX-770, indicated robust activation of mutant CFTR, including G551D expressed in heterologous cell culture systems and primary airway epithelial cell monolayers. The underlying mechanism of this agent is through augmentation of the open probability (P o ), as judged by singlechannel analysis of excised membrane patches [21 ] . The agent is highly specific to human (but not murine) CFTR, a characteristic shared by CFTR potentiators identified by other developmental strategies, and likely indicative of a protein conformation in human CFTR that is dependent on the human amino acid sequence [22] . Although the binding site of this molecule has not been reported, other agents (e.g. VRT-532) that exhibit potentiator activity have been shown to directly bind F508del CFTR as indicated by protease stability experiments [22] , and have also been shown to increase the ATPase activity (in addition to chloride conductance) of G551D CFTR [23 ] .
Testing of VX-770 has been conducted in CF individuals harboring at least one G551D CFTR mutation. Preliminary findings from a two-part phase 2 randomized, double-blind, placebo-controlled, dose-ranging clinical trial to evaluate safety, efficacy, and pharmacokinetics of VX-770 were recently reported [24] . Results of this two-part study indicated significant and dose-dependent improvements of sweat chloride (remarkably, mean sweat chloride achieved the diagnostic threshold at the most efficacious doses tested), improvement of CFTR-dependent chloride conductance in the airways as measured by nasal potential difference (NPD), and a significant increase in lung function over 2 weeks. The second part of this study confirmed initial findings, established that beneficial effects on ion transport and lung function were sustained at 4 weeks, and indicated a positive trend in measures of respiratory quality of life (e.g. the Cystic Fibrosis Questionaire-Revised (CFQ-R), a validated patient outcome measure) [25, 26] . These results represent the first evidence that any drug treatment improves CFTR activity in the airways (thus addressing the basic CF defect), corrects the sweat chloride abnormality, and ameliorates lung function in CF individuals. The results firmly establish CFTR as a viable therapeutic target in CF and support confirmatory studies of VX-770 in large randomized placebo-controlled studies. VX-770 has now progressed to phase 3 testing in CF individuals harboring G551D (Clinical Trials.gov reference numbers NCT00909532 and NTC00909727) and phase 2 testing in individuals homozygous for F508del (Clinical Trials.gov reference number NCT00953706). An important question to be addressed in these long-term studies is the relationship between measures of CFTR activity and degree of lung function improvement, as a correlation between these parameters was not observed in the preliminary analysis of the phase 2 study [26] .
Correction of F508del cystic fibrosis transmembrane conductance regulator misprocessing
Significant effort has been directed toward the goal of correcting the folding of F508del CFTR, thus restoring ion channel activity to the misfolded protein. A diverse array of cellular targets have been explored, commensurate with the large number of proteins now known to interact with CFTR biogenesis. Agents such as 4-phenyl butyrate downregulate Hsc70 (or other cell chaperones) central to the folding process, and represent an early example of compounds tested in the clinic [27, 28] . Other more recent efforts have resulted from high-throughput library screens for chloride channel function following incubation of test compounds with F508del expressing cells [17, 29, 30 ] . A number of these strategies have identified F508del correctors that may address cell biogenesis through chaperone pathways. Pharmacologic activity of such agents has also been reported to augment F508del CFTR half-life in the plasma membrane through altered surface recycling attributed to features of the cellular processing machinery [31] or reduced endocytic trafficking [32 ] . This class of agents may be potential drug development candidates if their safety in vivo is confirmed. Other compounds have been shown to directly interact with CFTR [33 ,34 ] and may offer greater specificity than agents that alter general aspects of cell folding or cellular quality control.
Initial results of a phase 2 trial of VX-809, a lead F508del CFTR corrector in the Vertex program, established that systemic administration of the compound for 4 weeks modestly improved sweat chloride at the highest dose tested compared with placebo [35]. These remarkable results further demonstrate that rescue of F508del CFTR in human individuals is achievable by a systemically delivered small molecule; although no effect on NPD or lung function was observed in the first clinical trial with this agent, ongoing efforts to enhance the degree of CFTR rescue to levels that also clearly confer clinically meaningful improvements in lung function are in progress. One straightforward approach is to coadminister a potentiator of CFTR channel gating. Because F508del CFTR exhibits other defects in addition to misfolding, including abnormal channel gating and membrane residence time, this strategy provides a high likelihood of increasing F508del CFTR following treatment with VX-809, as indicated by in-vitro results with combination therapy [36] .
Other discovery platforms seek to identify agents that augment F508del CFTR folding, independent of ion channel function. Using a trafficking assay based on epitope tagged CFTR, phosphodiesterase inhibitors including sildenafil and other active analogues have been shown to improve surface localization of the mutant protein. The same agents augment short-circuit current in F508del CFTR expressing cell lines [37] and enhance NPD in CF mice [38, 39 ] . More recently, the orally bioavailable compound glafanine was identified using the same assay [40] . Other approaches to discover F508del CFTR correctors utilize fluorescently tagged CFTR labels [41] . Cell-free systems to examine the stability of purified NBD1, CFTR folding (as judged by proteolytic degradation patterns), or other methods may complement available cell-based screens.
The global cellular response to misfolded protein may also represent a target. Histone deacetylases (HDAC) have far-ranging effects on gene expression, and specific members of the HDAC family are involved in the ERassociated degradation pathway promoting degradation of F508del CFTR [42] . Treatment of CF cells with HDAC inhibitors can modulate ER stress, and HDACs such as suberoylanilide hydroxamic acid, as well as siRNA-silencing of HDACs, increase levels of F508del CFTR in the cell membrane [43 ] . The combination of approaches such as these reveal a number of potential pharmacologic agents for F508del correction. Additive or synergistic rescue of F508del CFTR using more than one such strategy may offer hope of achieving ion transport activity sufficient to confer a normal phenotype in CF respiratory epithelia [30 ,44] .
Translational readthrough of premature termination codons
Readthrough of PTCs represents another exciting approach to address the underlying cause of CF, and many other genetic diseases caused by PTCs. Certain aminoglycosides and other agents have the capacity to interact with the eukaryotic rRNA within the ribosomal subunits [45] . Although this interaction is much weaker than that seen in prokaryotes and is distinct from the primary cause of aminoglycoside toxicity in human individuals, it can modestly reduce the fidelity of eukaryotic translation by interrupting the normal proofreading function of the ribosome [46] [47] [48] [49] [50] [51] [52] . Insertion of a near cognate amino acid at a premature stop codon allows protein translation to continue until one of several stop codons normally present at the end of the mRNA transcript is reached and properly utilized [48] . The specificity of the strategy has been attributed to greater stop codon fidelity at the authentic (3 0 ) end of mRNA and has been established in vitro by demonstrating no detectable elongation beyond native stop codons [53] [54] [55] [56] together with an acceptable safety profile in both preclinical and phase I and II clinical studies.
Proof of concept experiments with aminoglycosides established that premature stop mutations within CFTR in human individuals can be suppressed, resulting in the synthesis of full-length, functional CFTR protein [53] [54] [55] [56] 57 ] . As expected, the approach is not specific to CF, as in-vitro experiments have demonstrated efficacy of the approach in other diseases caused by PTCs, including Duchenne's muscular dystrophy, Hurler's syndrome, ceroid lipofuscinosis, nephropathic cystinosis, and expression of mutated p53 [46, 51, [58] [59] [60] [61] , and has also demonstrated success in mouse models of CF [62, 63] . In a double-blind, placebo-controlled trial from Israel using gentamicin, bioelectric correction of nasal ion transport was seen specifically in individuals with nonsense mutations, and, as expected, not observed in CF controls homozygous for F508del [55] . This followed two small pilot trials also indicating restoration of chloride secretion in CF individuals harboring stop codons [54, 56] . A trial examining systemic gentamicin in seven French individuals with Y122X CFTR, a mutation highly susceptible to readthrough, also indicated rescue of CFTR activity in the airway and sweat duct [53] . Not all aminoglycoside trials in CF have demonstrated success, suggesting low levels of protein correction, or the possibility of genetic founder effects. Regardless, due to the known toxicity and poor bioavailability of aminoglycosides, more efficacious agents that avoid undesirable properties of aminoglycosides will be required in CF, where 10% of CFTR function is likely required to confer clinical improvement based on genotype-phenotype correlations in the disease [64] . One such approach includes medicinal chemistry approaches to isolate the antimicrobial, toxic, and readthrough effects of the base scaffolds, a strategy demonstrating initial success using in-vitro reporters of efficacy and toxicity [65 ] , and cell-based and animal-based models of CFTR rescue [66] . Another is to identify entirely novel compounds that confer advantages over the aminoglycoside class.
PTC Therapeutics, Inc. (South Plainfield, New Jersey, USA), screened and evaluated over 800 000 compounds to identify new agents more suitable than gentamicin for inducing translational readthrough [67] . The effort resulted in the identification of ataluren (formerly PTC124), a novel, orally bioavailable agent that exhibits PTC suppression at concentrations readily achievable in serum [62, 68] . The agent is also efficacious in vivo in an animal model of nonsense mediated CF [69] . Surface localized full-length CFTR was substantially improved in cross-sections of intestinal tissues following administration to CF mice carrying the G542X mutation and restored CFTR function by Ussing chamber analysis in intestinal samples of mice after 2 weeks of treatment with ataluren. The drug is well tolerated in normal and CF individuals [68] , leading to a series of clinical trials examining ataluren in CF individuals harboring nonsense alleles.
Two recent studies utilizing orally administered ataluren in Israel [70 ] and France/Belgium [57 ] detected rescue of CFTR activity (as assayed by the NPD) in open label, two-dose crossover phase II trials in CF individuals possessing PTCs. Similarly to the results of clinical studies with gentamicin, a complementary trial conducted at United States centers did not demonstrate improvement in CFTR function [71] , raising questions as to the lack of efficacy. The reasons for failure are not completely clear, but include the challenge of NPD studies in multicenter trials (a critique that has been subsequently addressed by improvement in the testing method [72] ), relative susceptibility of the W1282X mutation found commonly in Israel [73] , and genetic founder effects, including the degree of CFTR mRNA expression at baseline [70 ,74] . Alternatively, ataluren has recently been reported to induce stabilization of the firefly luciferase [75 ] , which induces a paradoxical increase when used as a reporter of PTC suppression [76] . Although the concentration that is observed is greater than the dose required to induce readthrough, it has raised the question as to whether chemical optimization using an alternate readthrough assay might yield even more efficacious compounds.
A follow-up study examining the effect of prolonged treatment with ataluren (3 months) in 19 individuals previously studied for 2 weeks indicated significant improvement in CFTR activity following a 3-month treatment period, and was accompanied by a trend toward improved pulmonary function and a significant reduction in quantitative cough [77] . Importantly, all individuals who failed to respond to treatment in the previous 2-week cycle exhibited an NPD response after 3 months of therapy, suggesting time-dependent effects in individuals resistant to initial treatment [77] . Based on these results, a phase 3 randomized, blinded, placebo-controlled study is currently ongoing and is of sufficient size and duration to discern time-dependent effects on a CF population harboring a diverse array of CFTR PTCs (Clinical Trials.gov reference number NCT00803205).
Conclusion
Discovery of the CFTR gene and an improved understanding of the role of ion transport in disease pathogenesis have led to the development of new therapies that target the underlying defect in cystic fibrosis. Several high-throughput-based screening efforts have come to fruition, demonstrating rescue of the CFTR protein in the clinic in phase 2 trials. A new generation of strategies that address F508del CFTR misfolding promise new opportunities to address the most common cause of CF. Combined with steady improvements in the supportive care of CF, these advances promise an optimistic future for CF patients and their families. The success here of direct interaction with a small-molecule corrector with mutant CFTR demonstrates the possibilities for wider application in other protein folding disorders.
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